AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 293: H2624-H2625, 2007. First published September 7, 2007; doi:10.1152/ajpheart.00923.2007
0363-6135/07 $8.00
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/5/H2624    most recent
00923.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harken, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harken, A. H.

EDITORIAL FOCUS

The world of inhibitory {kappa}B

Alden H. Harken

University of California San Francisco-East Bay Department of Surgery, Oakland, California

A LIFE IS A MINEFIELD of inflammatory opportunities. The evolutionary conservation of these cellular pathways supports the counterintuitive conclusion that post-stress/injury inflammation must be good. Of the multiple similarities between rodents and humans, the autocrine and paracrine control systems are perhaps the most striking.

In a recent article in American Journal of Physiology-Heart and Circulatory Physiology, Moss et al. (9) address the pathogenesis of cardiovascular disease. Atherosclerosis has become the most frequent cause of both morbidity and mortality of both men and women in the United States. The authors target a cardiomyocyte-signaling pathway that generates myocardial tumor necrosis factor (TNF). TNF is produced by both resident macrophages and cardiomyocytes themselves in response to ischemia-reperfusion, sepsis, chronic heart failure, viral myocarditis, and transplant allograft rejection (7). There is direct correlation between myocardial TNF and myocardial mechanical dysfunction in humans (14). And, an equally direct relationship exists between left ventricular function and survival in all of us (10). Thousands of animal (9) and human (1) studies have identified the transcriptional regulator, nuclear factor-{kappa}B (NF-{kappa}B), at the nexus of this proinflammatory cellular program. NF-{kappa}B resides in the cytosol as a heterodimeric construct of p65 and p50 subunits. In the unstimulated cardiomyocyte, inhibitory {kappa}B (I{kappa}B) binds the NF-{kappa}B heterodimer, preventing its translocation into the nucleus. As delineated by Moss et al. (9), the I{kappa}B kinase (IKK) complex is made up of IKK{gamma}, IKK{alpha}, and IKKbeta subunits. Multiple common clinical injuries, including vascular shear stress (11) and ischemia-reperfusion (13), tip over the most proximal IKKbeta-kinase-activating domino. IKKbeta phosphorylates IKK{alpha}, targeting it for polyubiquitination and degradation. A dismembered I{kappa}B can no longer prevent the nuclear translocation of NF-{kappa}B with consequent proinflammatory results. Whether you subscribe to the chlamydia (15)-initiated infectious disease hypothesis of atherogenesis or the shear stress/vascular injury explanation (12), NF-{kappa}B is common to both.

Prevention of atherosclerosis is a logical and appealing public health goal. Nonspecific NF-{kappa}B inhibitors like adenosine (6) or N-acetylcysteine (9) prevent downstream effects of this multifaceted regulator of transcription. The consequences of chronic NF-{kappa}B depression, however, are unresolved, and NF-{kappa}B does protect against ischemia-reperfusion-induced cardiomyocyte apoptosis (8). So, consistent with its evolutionary conservation, is NF-{kappa}B a friend or a foe (5)?

NF-{kappa}B plays a pivotal role in constructive cardiac preconditioning in both rabbits (16) and humans (3). NF-{kappa}B also promotes TNF production (7), which induces apoptosis (2). So, if chronic inhibition of NF-{kappa}B is not assuredly safe, must we restrain our therapeutic enthusiasm and just target acute coronary syndromes (ACSs)? That is still a big problem. More than one million Americans die each year of ACS. The problem, of course, is, When do you treat? Patients do not schedule or plan their heart attacks. The beauty of the current contribution by Moss et al. (9) is that specific pharmacological antagonism of the NF-{kappa}B inflammatory pathway reduced left ventricular infarct size when the IKKbeta inhibitor was provided before the experimental coronary artery ligation. But, clinically, you would need to treat a lot of angry, high-strung executives to time and catch their heart attacks just right.

Consequently, Moss et al. (9) introduced the IKKbeta inhibitor at a clinically relevant 2 h following the coronary occlusion and still accomplished a reduction in infarct size. Now, we can do that. The thrombolytic agent, alteplase, has been successfully administered, in large clinical series, to stroke victims in less than 3 h from onset of symptoms (4).

Moss et al. (9) have produced a hypothesis-driven, mechanistically based, clinically relevant study. We can derive relevant conclusions based upon our data. Do we have an opportunity, or responsibility, to take the next step from cells to humans to groups of people? In November 1947, the United Nations passed a resolution that formally partitioned the Middle East and established the birthday of Israel as a nation. National, like cellular, partition obligates destructive inflammatory and apoptotic programs. This pattern is characterized during myocardial infarction and was certainly replicated in Israel. The trajectory has proven unavoidable in India in 1948 and in Bosnia in 1995. Now we are watching it evolve in Iraq. Can scientists identify, promote, and target the administration of a geopolitical IKKbeta?

FOOTNOTES


Address for reprint requests and other correspondence: A. H. Harken, Univ. of California San Francisco-East Bay Dept. of Surgery, 1411 E. 31st St., Oakland, CA 94602 (e-mail: harkena{at}surgery.ucsf.edu)

REFERENCES

  1. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107: 3–6, 2001.[CrossRef][Web of Science][Medline]
  2. Caruso JA, Mathieu PA, Joiakim A, Zhang H, Reiners JJ Jr. Aryl hydrocarbon receptor modulation of tumor necrosis factor-alpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent. J Biol Chem 281: 10954–10967, 2006.[Abstract/Free Full Text]
  3. Cleveland JC Jr, Meldrum DR, Rowland RT, Cain BS, Meng X, Gamboni-Robertson F, Banerjee A, Harken AH. Ischemic preconditioning of human myocardium: protein kinase C mediates a permissive role for {alpha}1-adrenoceptors. Am J Physiol Heart Circ Physiol 273: H902–H908, 1997.[Abstract/Free Full Text]
  4. De Keyser J, Gdovinova Z, Uyttenboogaart M, Vroomen P, Luijckx G. Intravenous alteplase for stroke. Beyond the guidelines and in particular clinical situations. Stroke 38: 2612–2618, 2007.[Abstract/Free Full Text]
  5. Kukreja RC. NFkappaB activation during ischemia/reperfusion in heart: friend or foe? J Mol Cell Cardiol 34: 1301–1304, 2002.[CrossRef][Web of Science][Medline]
  6. Li C, Kao RL, Ha T, Kelley J, Browder IW, Williams DL. Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol 280: H1264–H1271, 2001.[Abstract/Free Full Text]
  7. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274: R577–R595, 1998.[Abstract/Free Full Text]
  8. Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, Sivasubramanian N, Olson EN, Entman ML, Mann DL. Nuclear factor-kappaB protects the adult cardiomyocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation 108: 3075–3078, 2003.[Abstract/Free Full Text]
  9. Moss NC, Stansfield WE, Willis MS, Tang R, Selzman CH. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 293: H2248–H2253, 2007.[Abstract/Free Full Text]
  10. Ndrepepa G, Mehilli J, Martinoff S, Schwaiger M, Schömig A, Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol 50: 149–156, 2007.[Abstract/Free Full Text]
  11. Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH. Lipisomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84: 867–875, 1999.[Abstract/Free Full Text]
  12. Selzman CH, Shames BD, McIntyre RC, Banerjee A, Harken AH. The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation. Ann Thorac Surg 67: 1227–1231, 1999.[Abstract/Free Full Text]
  13. Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 84: 120–125, 2007.[Abstract/Free Full Text]
  14. Wang M, Markel T, Crisostomo P, Herring C, Meldrum K, Lillemoe KD, Meldrum DR. Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6 but not p38 MAPK or IL-1{alpha}. Am J Physiol Heart Circ Physiol 292: H1694–H1699, 2007.[Abstract/Free Full Text]
  15. Wang SS, Tondella ML, Bajpai A, Mathew AG, Mhranpour P, Li W, Kacharava AG, Fields BS, Austin H, Zafari AM. Circulating Clamydia pneumoniae DNA and advanced coronary artery disease. Int J Cardiol 118: 215–219, 2007.[CrossRef][Web of Science][Medline]
  16. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, Bolli R. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84: 1095–1109, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
A. V. G. Edwards, M. Y. White, and S. J. Cordwell
The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/5/H2624    most recent
00923.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harken, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harken, A. H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.